natgillin/translations-raw huggingface dataset:
greater than or equal to 5 litres, greater than or equal to 10 litres, greater than or equal to 15 litres, greater than or equal to 20 litres, greater than or equal to 25 litres, greater than or equal to 50 litres, or greater than or equal to 100 litres; or 
(di) veći od ili jednak 5 1, veći od ili jednak 10 I, veći od ili jednak 15 1, veći od ili jednak 20 1, veći od ili jednak 25 L veći od ili jednak 50 I, ili veći od ili jednak 100 I; ili
The compound according to Claim 2, wherein R3 represents indolyl which may be substituted with C1-6 alkyl or -O-C1-6 alkyl. 
Tvar u skladu s patentnim zahtjevom 2, pri čemu predstavlja indolil koji može biti supstituiran C1-6 alkilom ili -O-C1-6 alkilom.
Embodiments of the present invention further include: 
Datum objave europske prijave patenta:
in which the melting chamber walls comprise double steel walls separated by circulating cooling liquid, preferably water. 
12.23 gdje su stijenke komore za taljenje dvostruke čelične stijenke, razdvojene kružećom rashladnom tekućinom, po mogućnosti vodom;
Between 0.5 hours and I hour, the top line is the 160µg/mg dose (■), and the lowest line is 65µg/mg (A), although all lines are very similar. 
Između 0,5 sati i 1 sata, gornja linija je doza od 160ug/mg (1), a najniža linija je 65ug/mg (A), premda su sve linije vrlo slične.
Protrusions may be provided on one side of the inner part, and which pushes the element(s) towards an opposite side of the inner part, when the packaging is closed. 
Izbočenja mogu biti predviđena na jednoj strani unutarnjeg dijela i ona potiskuju element(e) prema suprotnoj strani unutarnjeg dijela, kada je pakiranje zatvoreno.
The method of claim 1, wherein the single parameter, xwpSEQ, determined in step c) is also computed from meta-information about the media stream. 
Metoda prema patentnom zahtjevu 1, naznačena time da je jednostruki parametar xwpSEQ, određen u koraku c), izračunat iz metainformacije iz medijskog toka kao što je zasebna konfiguracija i skrivanje gubitka paketa.
The process of claim 13, wherein the temperature profile during the curing step c) shows a plateau-like form and wherein said temperature is at least about 68° C. and the curing time is in the range of from about 30 minutes to about 20 hours. 
Postupak prema zahtjevu 13, naznačen time da temperaturni profil tijekom koraka stvrdnjavanja pokazuje oblik platoa i gdje je navedena temperatura poželjno barem oko 68 "€ i gdje je vrijeme stvrdnjavanja poželjno u rasponu od oko 30 minuta do oko 20 sati.
The method according to any one of the preceding claims, wherein the method further comprises a step e), wherein step e) comprises removing at least part of one cation from the AX-REED liquid while retaining at least 65% of said at least one micro-nutrient in said liquid, thereby obtaining a CX-REED liquid, wherein said cation is removed through an Cation Exchange Reverse Electro-Enhanced Dialysis (CX-REED) membrane stack, said membrane stack containing 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time što postupak nadalje obuhvaća korak e), pri čemu korak e) obuhvaća uklanjanje najmanje dijela jednog kationa iz tekućine AX-REED uz zadržavanje najmanje 65 % navedene najmanje jedne mikro hranjive tvari u navedenoj tekućini, te se tako dobiva tekućina CX-REED, pri čemu se navedeni kation uklanja putem stoga membrana za kationsku izmjenu reverznom elektro poboljšanom dijalizom „Cation Exchange Reverse Electro-Enhanced Dialysis“ (CX-REED), te navedeni stog membrana sadrži
An antibody, or a derived compound or functional fragment of same, according to claim 6, characterized in that it comprises a heavy chain comprising the CDR-H1 of the sequence SEQ ID No. 11, the CDR-H2 of the sequence SEQ ID No. 12 and the CDR-H3 of the sequence SEQ ID No. 6. 
– laki lanac koji prema Kabat sadrži CDR-L1 sekvencije SEQ ID No. 46, CDR-L2 sekvencije SEQ ID No. 47 te CDR-L3 sekvencije SEQ ID No. 41, te – teški lanac lanac koji prema Kabat sadrži CDR-H1 sekvencije SEQ ID No. 48, CDR-H2 sekvencije SEQ ID No. 49 te CDR-H3 sekvencije SEQ ID No. 43.
Wind system (1) according to claim 16, characterised in that an end part (10) able to be oriented of said recovering system (8) is driven through a system composed of at least three ropes (31). 
Proces proizvodnje električne energije pomoću vjetrenog sustava (1) prema zahtjevu 41, naznačen time da spomenuti prvi motori (28) također imaju 1 funkciju generatora, koji proizvode električnu energiju putem rotacije spomenutih prvih vitala (24).
oxidising the compound of formula (2) obtained in step a to give a compound of formula (3): Also described are: 
H 9 OO b) oksidaciju spoja formule (2) da bi se dobio spoj formule (3): pi o
Number of patients (%) 
(21) Broj predmeta:
The system of claim 1 wherein the pressurized air from the pressurized air source and rate of pumping action of the pump are coordinated to produce misting action at the nozzle. 
Sustav prema zahtjevu 1, naznačen time što su zrak pod tlakom iz izvora zraka pod tlakom i brzina pumpanja usklađeni da izazovu formiranje magle na mlaznici.
Accordingly there is provided a compound of formula (1): wherein: 
PATENTNI ZAHTJEVI L Spoj formule (1):
The method according to claim 3, wherein when the terminal sends the encoded information through the physical uplink shared channel PUSCH, the encoded information is mapped to a position that is on the two sides of a demodulation pilot or reference signal and is adjacent to the demodulation pilot or reference signal through a channel interleaver. 
Postupak prema zahtjevu 2, naznačen time da terminal šalje kodirane informacije kroz PUSCH, i kodirane informacije se mapiraju na položaj resursa koji je na dvije strane demodulacijskog pilota ili referentnog signala u vremenskoj domeni i susjedan je s demodulacijskim pilotom ili referentnim signalom kroz kanalsko preplitanje, ili kodirane informacije se mapiraju na položaj resursa koji je na dvije strane demodulacijskog pilota ili referentnog signala u vremenskoj domeni i ima interval jedne frekvencijske podjele višestrukog pristupa jednostrukog nosioca, SC-OFDM, simbola s demodulacijskim pilotom ili referentnim signalom kroz kanalsko preplitanje.
PrG has the same meaning as in formula (III) and 
PrG ima isto značenje kao u formuli (III), a
reducing the compound of Formula XLIII to give a compound of Formula XLIV; 
Formula XLII! c. redukciju spoja Formule XLIII, čime se dobiva spoj Formule XLIV:
The present invention allows to overcome the above said problems by a synthesis that involves four steps and moreover uses, as starting compounds, compounds that may be easily synthesized or are commercially available. 
Ovaj izum omogućuje svladavanje gore rečenih problema sintezom koja uključuje četiri koraka i štoviše, kao početne spojeve koristi spojeve koji se lako sintetiziraju ili su komercijalno dostupni.
The resulting solid was collected, recrystallised from ethanol, and dried to give the title hemifumarate hemihydrate (2.4 g), m.p. 
Dobivena čista supstanca se sakuplja, prekristalizirala iz etanola i suši, čime se dobiva naslovni kemifumarat kemihidrat (2,4 g), t.t.
When a vacuum is applied between air-tight covering and molding wall, in other words, upon evacuation of the reinforcement package, the spirals will create an open space. 
Kad vakuum djeluje između neprodušnog pokrova i stijenke kalupa, drugim riječima, nakon evakuacije tijela za ojačanje, spirale će stvoriti otvoren prostor.
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use in a method according to embodiment 14, wherein the initial administration occurs after the subject has been found to have a genetic and/or biochemical marker of the LSD. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema zahtjevu 9, pri čemu se prvotna primjena odvija nakon što je za subjekta ustanovljeno da ima genetski i/ili biokemijski marker LSD-a.
a heavy chain comprising, according to IMGT, the CDR-H1 of the sequence SEQ ID No. 
antitijelo koji sadrži: – laki lanac koji prema Kabat sadrži CDR-L1 sekvencije SEQ ID No.
The method of claim 14, wherein the composition consists of a) 10% by weight terbinafine HCl, b) 0.3% by weight hydroxypropyl chitosan, c) 19.7% by weight purified water and d) 70% by weight ethanol. 
Pripravak prema patentnom zahtjevu 14, koji se sastoji od a) oko 10 % masenog udjela terbinafin HC1-a, b) oko 0,3 % masenog udjela hidroksipropil hitozana, c) oko 19,7 % masenog udjela pročišćene vode i d) oko 70 % masenog udjela etanola.
According to this third variant, the said formic or citric acid salt is preferentially a mono-, di- or tri-alkaline salt, and is more preferentially a salt of a cation of Group I or II of the Periodic Table of the Elements. 
Postupak prema zahtjevu 6, naznačen time da navedena sol mravlje ili limunske kiseline je mono-, di- ili trialkalna sol, te je poželjno sol kationa 1z skupine I ili II periodne tablice elemenata.
The volume will vary depending upon the amount of compactin and the boiling point of the water miscible organic solvent. 
Volumen će ovisiti o količini kompaktia i vrelištu organskog otapala koje se miješa s vodom.
The composition for use of any one of claims 1 to 5, wherein the composition is to be administered via an intravenous, intraarterial, intraperitoneal, intravesicular, subcutaneous, intrathecal, intrapulmonary, intramuscular, intratracheal, intraocular, transdermal, oral, or inhalation route. 
Pripravak za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time što se pripravak daje putem intravenoznog, intraarterijskog, intraperitonealnog, intravezikularnog, potkožnog, intratekalnog, intrapulmonalnog, intramuskularnog, intratrahealnog, intraokularnog, transdermalnog, oralnog ili inhalacijskog puta primjene.
is an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, or an optionally substituted heterocyclyl; 
je opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, ili opcijski supstituiran heterociklil;
In another embodiment, the salt of formula VII is rosuvastatin (-)-1-[(4-chlorophenyl)-phenyl-methyl]piperazinium salt which exhibits a powder x-ray diffraction pattern measured using CuKa-radiation having characteristic peak locations of 3.9, 10.0 and 16.9 ± 0.2 degrees 2θ, particularly 3.9, 10.0, 16.5, 16.9, 20.2 and 23.2 ± 0.2 degrees 2θ, more preferably exhibits a powder x-ray diffraction pattern substantially as shown in Fig. 3 . 
Sol prema zahtjevu 5, naznačena time, da je to rosuvastatin-(-)-1-[(4-klorofenil)-fenil-metillpiperazin-sol koja prikazuje uzorak difrakcije praha X-zraka mjeren uporabom CuKa-radijacije, s mjestima karakterističnih vršnih vrijednosti na 3,9, 10,01 16,9 +0,2 stupnjeva 20, poželjno na 3,9, 10,0, 16,5, 16,9, 20,2 i 23,2 +0,2 stupnjeva 20, i još bolje pokazuje uzorak difrakcije praha X-zraka uglavnom kako je prikazano na slici 3.
flushing the cation exchange column with purified water, followed by applying a 0.5 M sodium hydroxide solution to the cation exchange column for at least 4 hours, and 
apliciranje 0,5 M otopine natrijevog hidroksida u stupac na najmanje 4 sata, i - = regeneracija kromatografskog stupca kationske izmjene ispiranjem stupca pročišćenom vodom.
), hydrophobicity, hydrophilicity, linker flexibility, antigenicity, stability, and the like. 
), hidrofobnost, hidrofilnost, fleksibilnost veznika, antigenost, stabilnost i slično.
As the aforementioned dose examples are only to be understood as dose examples per single application (i. e. per puff) multiple application of the combinations according to the invention leads to multiple doses of the aforementioned examples. 
Kako goro navedene primjere doza treba smatrati isključivo primjerima doze za pojedinačnu primjenu (tj. po udisaju), višestruka primjena kombinacija sukladno predmetnom izumu vodi do višestrukih doza gore navedenih primjera.
The compounds of the first aspect of this invention (especially in the acid form) are inhibitors, typically selective inhibitors, of GST P1-1. 
Spojevi prvog aspekta ovog izuma (posebno u obliku kiseline) su inhibitori, tipično selektivni inhibitori, GST P1-1.
is a hydrogen atom or C1-6 alkyl optionally having 1 to 5 substituents selected from substituent group C; 
R'*je (a) Crg alkil koji opcijski ima 1 do 3 supstituenta odabrana od sljedećih:
emphysema, respiratory airways infection; 
- < emfizem, respiratorna infekcija dišnih puteva;
administering a second dose of the therapeutic agent having a concentration equal to or greater than the first concentration if the level of lyso-SPM in the peripheral tissue sample is less than or equal to the reference levels, 
Terapijsko sredstvo za uporabu prema patentnom zahtjevu 10, naznačeno time što se primjenjuje doza održavanja terapijskog sredstva koja sadrži rhASM u količini 1, 2, ili 3 mg/kg.
A method for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient by subcutaneous injection once per month a dose of about 70 mg to about 140 mg of an anti-calcitonin gene-related peptide (CGRP) receptor monoclonal antibody or antigen-binding fragment thereof, wherein the anti-CGRP receptor monoclonal antibody or antigen-binding fragment thereof comprises a CDRH1 having the sequence of SEQ ID NO:14, a CDRH2 having the sequence of SEQ ID NO:23, a CDRH3 having the sequence of SEQ ID NO:34, a CDRL1 having the sequence of SEQ ID NO:44, a CDRL2 having the sequence of SEQ ID NO:55, and a CDRL3 having the sequence of SEQ ID NO:65. 
postupku za sprječavanje ili smanjenje javljanja migrenske glavobolje kod pacijenta kojem je potrebno, ili postupku za profilaktičko liječenje pacijenta zbog migrene naznačeno time što postupak uključuje primjenu pacijentu protutijela anti-CGRP receptora ili njegovog ulomka koji veže antigen u dozi od oko 35 mg do oko 210 mg jednom mjesečno, pri čemu protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen sadrži CDRH1 koja ima sekvencu SEQ ID NO:14, CDRH2 koja ima sekvencu SEQ ID NO:23, CDRH3 koja ima sekvencu SEQ ID NO:34, CDRL1 koja ima sekvencu SEQ ID NO:44, CDRL2 koja ima sekvencu SEQ ID NO:55, i CDRL3 koja ima sekvencu SEQ ID NO:65.
The compound of claim 1 selected from the group-consisting of: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što ga se bira iz skupine koju čine:
A composition comprising an effective amount of a compound or pharmaceutically acceptable salt of the compound of any of claims 1-4 and a pharmaceutically acceptable vehicle or carrier. 
Pripravak naznačen time da sadrži učinkovitu količinu spoja ili farmaceutski prihvatljive soli spoja prema zahtjevu 1 ili zahtjevu 2 i farmaceutski prihvatljiv nosač ili prijenosnik.
Wind generator according to Claim 1, characterized in that said radial elements (6) have the same length and are equally spaced from each other and in that said platform is provided with suitable anchoring means 
Vjetrogenerator temeljem zahtjeva 1, naznačen time što navedeni radijalni elementi (6) imaju istu dužinu i jednako su razmaknuti jedan od drugoga i time što navedena platforma ima odgovarajući način sidrenja.
The present invention is further directed to the use of a water soluble film forming agent as an additive in a nail topical formulation. 
Ovaj izum je nadalje usmjeren k upotrebi vodotopivog agensa koji tvori film, kao aditiva u topikalnoj formulaciji za nokte.
The method of claim 1, wherein R′″ is selected from the group consisting of hydroxy, benzyloxy, ethoxy, hydrogen, thiol, methoxy, methylcarbonyloxy, and phenyl. 
Spoj prema zahtjevu 27, naznačen time da R"' je odabran iz skupine koja sadrži: hidroksi; benziloksi; etoksi;
A compound according to claim 1, which is of formula (VI) wherein R1 is halogen, methyl, cyano, nitro or trifluoromethyl; R2 is cyano, halogen or nitro; R3 is hydrogen, halogen or methyl; R4 is hydrogen or methyl; R5 is hydrogen or C1-3 alkyl, and wherein A is any one of the following groups or tautomers thereof: 
je vodik, halogen ili C1-7 alkil. Spoj prema zahtjevu 1, naznačen time, da ima formulu (VI) [image] pri čemu je R1 halogen, metil, cijano, nitro ili trifluorometil; R2 je cijano, halogen ili nitro; R3 je vodik, halogen ili metil; R4 je vodik ili metil; i R5 je vodik ili C1-3 alkil.
A “therapeutically effective amount” is intended to mean the amount of the inventive salt that, when administered to a subject in need thereof, is sufficient to effect treatment for disease conditions alleviated by the inhibition of protein kinase activity. 
Uporaba terapeutski učinkovite količine soli prema zahtjevu 1, naznačena time, da je za proizvodnju lijeka za liječenje bolesti koja odgovara inhibiciji djelovanja proteinske kinaze.
Kits used for assessment of the serum biomarkers: 
Datum podnošenja europske prijave patenta:
A wound dressing comprising a layer in the form of a strip characterised in that the strip comprises gel-forming fibres, the strip having longitudinal lines of stitches formed from a thread and transverse lines of stitches formed from a thread, where the thread is nylon, Tencel, polyolefin, polyurethane, polyester or cellulosic and the wound dressing is for use in cavity wounds or sinus wounds. 
PATENTNI ZAHTJEVI Povoj za rane koja sadrži sloj u obliku trake naznačen time što traka sadrži vlakna koja formiraju gel, što traka ima uzdužne štepove formirane koncem i poprečne štepove formirane koncem, pri čemu je taj konac najlon, Tencel, poliolefin, poliuretan, poliester ili je celulozni i što je prekrivka za rane za primjenu u ranama u šupljinama ili ranama u sinusima.
According to the patent application No. 
Datum podnošenja europske prijave patenta:
Squalene synthesis inhibitors belong to a class of drugs that lower blood cholesterol levels by inhibiting synthesis of squalene. 
Inhibitori sinteze skvalena pripadaju skupini spojeva koji snižavaju nivoe holesterola u krvi inhibicijom sineze skvalena.
with benzamide hydrochloride compound having the formula (8-2), 
R2aHC s benzamid hidrokloridom formule (8-2), H
For example the material may contain a filler, typically ca. 20%. 
Na primjer, takav materijal može sadržavati punilo, tipično oko 20%.
The method of embodiment 28, wherein the human retinal pigmented epithelial cells are ARPE-19 cells deposited with the American Type Culture Collection (ATCC) as Accession No. 
Postupak prema patentnom zahtjevu 11, naznačen time što su humane retinalne pigmentirane epitelne stanice ARPE-19 stanice deponirane kod American Type Culture Collection (ATCC) kao pristupni br.
In further embodiments, the antibody is a chimeric or humanized antibody or a fragment of a natural antibody. 
Uporaba sukladno zahtjevu 2, pri čemu je protutijelo kimerično ili humanizirano protutijelo ili fragment protutijela koji se selektivno veže za antigen povezan s tumorom.
The composition of claim 1 wherein said copper carboxylate is selected from the group consisting of copper acetate, copper naphthenate, copper quinolinolate, copper stearate, copper benzoate, copper ethylhexanoate, copper rosinates, and combinations thereof. 
Sastav prema zahtjevu 1, naznačen time da je bakar-karboksilat odabran iz skupine, koja se sastoji iz bakar-acetata, bakar-naftenata, bakar-kinolinolata, bakar-stearata, bakar-benzoata, bakar-etilheksanoata, bakar-rezinata i njihovih kombinacija.
The compound according to any of claims 1 to 12 for use in the treatment and/or prophylaxis of pain, selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain. 
Spoj prema bilo kojem od patentnih zahtjeva 1 do 12 naznačen time da je za uporabu za liječenje i/ili profilaksu bola odabranog iz skupine koju čine akutna bol, kronična bol, neuropatska bol, bol u mišićima, visceralna bol i upalna bol.
checking the type of data symbol according to a sequence set to change the type of data symbol used in the OFDM transmitting system; and 
provjere vrste simbola podataka prema istom redoslijedu koji se koristi kod OFDM uređaja za prijenos.
The heat exchanger 70 can be cooled, for example by means of water or air via cooling ribs 85 or can be connected to a Peltier cooling element for electrical cooling. 
Izmjenjivač topline 70 se može ohladiti, na primjer pomoću vode ili zraka preko rebara za hlađenje 85 ili se može spojiti na Peltierov element za hlađenje za električno hlađenje.
A pharmaceutical composition comprising additionally to a compound of formula 1, according to any one of claims 1 to 6, a pharmaceutically active compound selected from the group consisting of betamimetics, anticholinergics, corticosteroids, PDE4-inhibitors, LTD4-antagonists, EGFR-inhibitors, Cathepsin C inhibitors, CRTH2 inhibitors, 5-LO-inhibitors, Histamine receptor antagonists and SYK-inhibitors, but also combinations of two or three active substances. 
Farmaceutski pripravak, naznačen time, da obuhvaća dodatno uz spoj formule 1 u skladu s bilo kojim od patentnih zahtjeva 1 do 8, farmaceutski aktivni spoj koji je odabran iz skupine koja se sastoji od betamimetika, antikolinergika, kortikosteroida, PDE4inhibitora, LTD4antagonista, EGFRinhibitora, katepsin C-inhibitora, CRTH2-inhibitora, 5LOinhibitora, antagonista histaminskog receptora i SYKinhibitora, ali također od kombinacija od dvije ili tri aktivne tvari.
The anti-IL-5 antibody for the use according to claim 5, wherein said subcutaneous dose is to be administered one to three times. 
Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s patentnim zahtjevom 4, naznačeno time što navedenu supkutanu dozu treba primijeniti jednom do tri puta.
A pharmaceutical composition comprising a polymorphic form according to clause 1 and at least one pharmaceutically acceptable carrier or excipient. 
Farmaceutski pripravak, naznačen time što sadrži polimorfni oblik u skladu s patentnim zahtjevom 1 i najmanje jedan farmaceutski prihvatljivi nosač ili pomoćnu tvar.
to 10 mg of the peptide having the amino acid sequence of SEQ ID NO: 2, preferably 0.1, 0.5 or 1 mg of the peptide; and to 0.5 mg of an adjuvant, preferably human granulocyte macrophage-colony stimulating factor (GM-CSF), wherein the booster composition is formulated for intradermal injection. 
(1) pripravak cjepiva koji sadrži 1 mg peptida koji sadrži sekvencu amino kiseline SHQ ID. NO:2, 1 0.125 ili 0.250 mg humanog stimulirajućeg faktora kolonije granulocita/makrofaga (GM-CSF) kao adjuvanta, pri čemu je pripravak cjepiva formuliran za davanje kao tri do šest mjesečnih injekcija, poželjno kao intradermalne injekcije; te
or A1 and A2 are taken together with their attached nitrogen to form a ring selected the group consisting of azetidinyl, piperidinyl, pyrrolidinyl, wherein said ring is optionally substituted with up to three substituents independently selected from the group consisting of F, CF3, CH3, -CN, and CH2OH; 
ili Ai A se uzimaju zajedno sa njihovim vezanim dušikom da se obrazuje prsten koji je izabran iz grupe koja obuhvaća azetidinil, piperidinil, pirolidinil, PL S den pri čemu spomenuti prsten je po potrebi supstituiran sa do tri supstituenata nezavisno izabranih iz grupe koja obuhvaća F, CF3, CH, -CN, i CHLOH;
and n are as hereinbefore defined, in the form of a salt, such as a hydrohalide, in the presence of an inorganic base, such as NaH or an organic base, such as BEMP, e.g., in a polar aprotic solvent, such as N,N-DMF; the reaction may be carried out at 10-40° C., conveniently at ambient temperature. 
R?in su definiran kao ovdje ranije, u obliku soli, kao što je hidrohalogenid, u prisutnosti anorganske baze, kao što je NaH ili organske baze, kao što je BEMP, npr. u polarnom aprotonskom otapalu, kao što je N,N-DMF; reakciju se može provesti pri 10-40"C, prikladno pri sobnoj temperaturi.
providing an aminooxy compound comprising a second reactive group, wherein the aminooxy compound is chosen from compounds of wherein n is chosen from integers ranging from 1 to 10, P is chosen from amino protecting groups, and Y is a second reactive group; and 
UNS H Formula lil pri čemu Y je druga reaktivna skupina, n je odabran od cijelih brojeva u rasponu od 1 do 10, i P je odabran od amino zaštitnih skupina.